188bet官网地址-188bet体育备用网址-188bet手机版188bet手机版

表1

Summary of relevant licensed janus kinase inhibitors (JAKi) and thrombotic concerns

JAKi and selectivity	Pharmaceutical company	Licensed indication	指出君威rding thrombosis	COVID-19 trials registered at ClinicalTrials.gov^#
JAK 1/2, baricitinib	Eli Lilly	Rheumatoid arthritis	August 2017: SmPC revised to include a warning of reports of DVT and PE in patients receiving baricitinib and advised caution for use in patients with risk factors for DVT/PE, such as older age, obesity, a medical history of these disorders, recent surgery or immobilisation April 2018: FDA black box warning for DVT PE, 2 mg OD approved (not 4 mg OD), due to thrombotic concerns	NCT04340232 NCT04362943 NCT04346147 NCT04358614 NCT04390464 NCT04320277 NCT04373044 NCT04321993 NCT04345289 NCT04365764 NCT04366206
JAK 1/2, ruxolitinib	Novartis	Myelofibrosis Polycythaemia	No safety alert for thrombosis	NCT04348071 NCT04355793 NCT04354714 NCT04362137 NCT04377620 NCT04334044 NCT04337359 NCT04331665 NCT04366232 NCT04374149 NCT04361903 NCT04338958 NCT04348695 NCT04359290
JAK 1/3, tofacitinib	Pfizer	Rheumatoid arthritis Psoriatic arthritis Ulcerative colitis	February 2019: FDA issued safety alert concerning thrombotic risk July 2019: FDA black box warning for DVT and PE, for the 10 mg BD dose (this higher dose is approved for ulcerative colitis) November 2019: EMA updated European product information with warning for thrombosis	NCT04390061 NCT04332042
JAK1, upadacitinib	Abbvie	Rheumatoid arthritis	August 2019: FDA black box warning for DVT, PE and arterial thrombosis	None
JAK2, fedratinib	Celgene公司	Myelofibrosis	No safety alert for thrombosis	None

It is not clear whether the coronavirus disease 2019 (COVID-19) trials excluded patients at risk of thrombosis or mandated thromboprophylaxis. SmPC: summary of medicinal product characteristics; PE: pulmonary emboli; DVT: deep venous thrombosis; FDA: Food and Drug Administration; OD: once daily; BD twice daily: EMA: European Medicines Agency.^#: n=27 as of 18 May 2020.